October 22, 2016
Neovac, a French company specializing in immunotherapies, will begin studying its interferon-alpha kinoid vaccine for the treatment of type 1 diabetes in collaboration with French researchers at the Cochin Hospital in Paris, according to a company press release
IFN-alpha kinoid produces polyclonal neutralizing antibodies to interrupt IFN-alpha. Overexpression of this protein is a signature of type 1 diabetes.
whether the neutralizing antibodies are effective on IFN-alpha.